Mid-Atlantic and Southeast Biotherapeutics Solution Specialists
BIOGRAPHY
DEC 03, 2020 10:30 AM PST
Accelerating vaccine development using a next generation microfluidic CE platform
Presented at:
Coronavirus Series
Speaker
Abstract
When producing a quality vaccine, all manufacturers must confirm the purity as well as the stability of their formulation and final product. Sample quantity and measurement time are often the throughput bottlenecks encountered during the process. As PerkinElmer’s LabChip GXII Touch addresses these specific gaps, we’ve developed a literature-centric webinar.
Learning Objectives:
1. The vaccine development and manufacturing process
2. The key applications of microfluidic CE in vaccine process development
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...